In a meta-analysis of 10 clinical studies covering 6219 patients, CEBPAbiallelic mutation was found to be associated with favorable clinical outcomes with regard to EFS and OS in patients with AML or CN-AML; conversely, no significant difference was found between CEBPAmonoallelic mutation and wild-type CEBPA in patients with AML or CN-AML [86]. Here, CEBPA is linked to acute myeloid leukemia.